Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | WRN | Q14191 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037886 | 0.83 | GLA (0.41) | ALDH1A1KMT2AMEN1GLA | |
| SCHEMBL30474637 | 0.75 | ALDH1A1 (0.38) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL57077 | 0.75 | ALDH1A1 (0.38) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL17756748 | 0.75 | ALDH1A1 (0.38) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| Sulfuric Acid SCHEMBL28284052 | 0.73 | MGLL (0.34) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL17329480 | 0.71 | CYP1A2 (0.38) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| Ethylene Glycol SCHEMBL4555859 | 0.71 | ALDH1A1 (0.35) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| Ethylene Glycol SCHEMBL1593589 | 0.71 | ALDH1A1 (0.35) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL17756764 | 0.68 | ALDH1A1 (0.33) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL7926166 | 0.68 | ALDH1A1 (0.33) | ALDH1A1HPGDCYP1A2CYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368907-B1 | Anti-Abeta antibodies and their use | HOFFMANN LA ROCHE (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-20130136747-A1 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE | MORPHOSYS AG (DE) | 2013-05-30 | — | — | US | disclosed |
| US-8329886-B2 | Nucleic acid molecules encoding anti-amyloid beta antibodies | HOFFMAN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225478-A1 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE | BARDROFF MICHAEL (DE) | 2012-09-06 | — | — | US | disclosed |
| US-8216577-B2 | Anti-Aβ antibodies and their use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-10 | — | — | US | disclosed |
| EP-2368907-A2 | Anti-Abeta antibodies and their use | F. Hoffmann-La Roche AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-7794719-B2 | Anti-amyloid β antibodies | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20100172907-A1 | Anti-Abeta antibodies and their use | BARDROFF MICHAEL | 2010-07-08 | — | — | US | disclosed |
| EP-1340424-B1 | Double transgenic, non-human mammalian animal model for Alzheimer's disease | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-7247766-B2 | Double transgenic mice overexressing human beta secretase and human APP-London | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050169925-A1 | Anti-amyloid beta antibodies and their use | HOFFMANN-LA ROCHE INC. | 2005-08-04 | — | — | US | disclosed |
| EP-1481008-A2 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-20030167486-A1 | Amyloid precursor proteins (APP); for treatment of Alzheimer's disease/neurodegenerative disorders; drug screening | HOFFMANN-LA ROCHE INC. | 2003-09-04 | — | — | US | disclosed |
| EP-1340424-A1 | Double transgenic animal model for Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003070760-A2 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-28 | — | — | WO | disclosed |
| US-5714149-A | Crosslinked antibodies and processes for their preparation | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| EP-0384624-B1 | Cross-linked antibodies and processes for their preparation | CELLTECH THERAPEUTICS LTD (GB) | 1995-06-21 | — | — | EP | disclosed |
| EP-0384624-A2 | Cross-linked antibodies and processes for their preparation | CELLTECH THERAPEUTICS LIMITED (GB) | 1990-08-29 | — | — | EP | disclosed |
| WO-1990009195-A1 | CROSS-LINKED ANTIBODIES AND PROCESSES FOR THEIR PREPARATION | CELLTECH LIMITED (GB) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136747-A1 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE | APP, APBA1, ABHD14B | ALDH1A1 3216/4885HPGD 3972/4885CYP1A2 4187/4885 |
| US-20100172907-A1 | Anti-Abeta antibodies and their use | APP, ABHD14B, IGLV6-57 | ALDH1A1 3654/4885HPGD 3520/4885CYP1A2 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.